ADCT ADC Therapeutics S.A. Return on Sales by Net Profit

The net profit margin of ADC Therapeutics (ADCT) demonstrates current business efficiency, where -95.70 reflects the latest value of the metric. ADC Therapeutics creates targeted therapy through partnerships with Mitsubishi Tanabe. The organization focuses on antibody-drug conjugates and the drug Zynlonta for the treatment of lymphomas. To maintain market share, the issuer is actively expanding its distribution network to counter pressure from major oncology behemoths.
Analytical breakdowns for ADC Therapeutics

For ADC Therapeutics (ADCT), which combines the development of oncology drugs with strict ESG waste disposal standards, this indicator reflects the efficiency of innovation monetization minus all operational and ethical costs. The metric is calculated as the ratio of net income to revenue, measuring the share of real income from every dollar of sales. Analyzing the actual net profit margin allows for the separation of short-term fluctuations from systemic trends in business sustainability.